Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

News Conference News TCT 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Michael O'Riordan

October 29, 2024

Will Semaglutide Change Cardiac Surgery? It Already Has

News Conference News EACTS 2024

Will Semaglutide Change Cardiac Surgery? It Already Has

Yael L. Maxwell

October 10, 2024

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

News Conference News ESC 2024

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

August 31, 2024

Marked LDL Lowering With Obicetrapib in HeFH: BROOKLYN

News Daily News

Marked LDL Lowering With Obicetrapib in HeFH: BROOKLYN

Michael O'Riordan

July 29, 2024

Weight-Loss Drug Tirzepatide Reduces Severity of Obstructive Sleep Apnea

News Daily News

Weight-Loss Drug Tirzepatide Reduces Severity of Obstructive Sleep Apnea

Michael O'Riordan

June 25, 2024

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

News Conference News ACC 2024

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

April 06, 2024

Increased Lp(a) Ups CV Risk Regardless of hs-CRP Level

News Daily News

Increased Lp(a) Ups CV Risk Regardless of hs-CRP Level

Yael L. Maxwell

February 15, 2024

Universal Risk Tool Works Well in Both Primary and Secondary Prevention

News Daily News

Universal Risk Tool Works Well in Both Primary and Secondary Prevention

Michael O'Riordan

February 01, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.